| Dr Jeremy Holzmacher Levin, MD | |
|
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
| (414) 955-1700 | |
| (414) 955-0072 |
| Full Name | Dr Jeremy Holzmacher Levin |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 11 Years |
| Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013350040 | NPI | - | NPPES |
| 1013350040 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | 82030 (Wisconsin) | Secondary |
| 208600000X | Surgery | 82030 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Froedtert Memorial Lutheran Hospital | Milwaukee, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Medical College Of Wisconsin Inc | 2668384371 | 1813 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.
Patient Portals are a trending item in the healthcare industry, but what does the term "Patient Portal" really mean? And more importantly, what can a Patient Portal do for you?
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the fourth quarter and year ended December 31, 2009. Total net revenue grew to $39,809,000, up 10% from $36,177,000 in the prior year fourth quarter. Same-facility net revenue growth was 6% for the quarter.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.
› Verified 8 days ago
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.
Patient Portals are a trending item in the healthcare industry, but what does the term "Patient Portal" really mean? And more importantly, what can a Patient Portal do for you?
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the fourth quarter and year ended December 31, 2009. Total net revenue grew to $39,809,000, up 10% from $36,177,000 in the prior year fourth quarter. Same-facility net revenue growth was 6% for the quarter.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.
› Verified 8 days ago
| Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.
Patient Portals are a trending item in the healthcare industry, but what does the term "Patient Portal" really mean? And more importantly, what can a Patient Portal do for you?
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the fourth quarter and year ended December 31, 2009. Total net revenue grew to $39,809,000, up 10% from $36,177,000 in the prior year fourth quarter. Same-facility net revenue growth was 6% for the quarter.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeremy Holzmacher Levin, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 955-1700 | Dr Jeremy Holzmacher Levin, MD 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 955-1700 |
News Archive
Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.
Patient Portals are a trending item in the healthcare industry, but what does the term "Patient Portal" really mean? And more importantly, what can a Patient Portal do for you?
NovaMed, Inc., a leading operator of ambulatory surgery centers in partnership with physicians, today announced results for the fourth quarter and year ended December 31, 2009. Total net revenue grew to $39,809,000, up 10% from $36,177,000 in the prior year fourth quarter. Same-facility net revenue growth was 6% for the quarter.
Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.
› Verified 8 days ago
Dr. Simin Golestani, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-5800 Fax: 414-805-8097 | |
Dr. David L Larson, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 8700 Watertown Plank Road, Wisconsin Athletic Club Bldg, Milwaukee, WI 53226 Phone: 414-805-3666 | |
Dr. John J Aiken, MD Surgery Medicare: Medicare Enrolled Practice Location: 9000 W Wisconsin Ave, Pediatric Surgery, Milwaukee, WI 53226 Phone: 414-266-6550 Fax: 414-266-6579 | |
Nicole M Zaremba, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2801 W Kinnickinnic River Pkwy Ste 145, Milwaukee, WI 53215 Phone: 414-385-2301 | |
Dr. Keith T Oldham, MD Surgery Medicare: Medicare Enrolled Practice Location: 9000 W Wisconsin Ave, Pediatric Surgery, Milwaukee, WI 53226 Phone: 414-266-6550 Fax: 414-266-6579 | |
William R Deshur, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2801 W Kk River Pkwy, Suite 330, Milwaukee, WI 53215 Phone: 414-649-3240 Fax: 414-649-3244 |